P. Semikova

Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)

I. Efremova, V. Ivashkin, R. Maslennikov, 2021, European Cytokine Network.

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19

V. Ivashkin, R. Maslennikov, M. Chipurik, 2023, Russian Journal of Gastroenterology, Hepatology, Coloproctology.

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

I. Efremova, V. Ivashkin, R. Maslennikov, 2021, Pulmonary Pharmacology & Therapeutics.